Key Highlights

  • Total revenues were $353.2 million, versus $120.7 million in the third quarter of 2025.
  • Net product Revenue climbed to $253.3 million from $108.1 million.
  • Loss from operations shrank to $11.6 million from $145.2 million.
  • Net loss per share attributable to common stockholders was $0.42, compared with $0.95.
  • Cash, cash equivalents and marketable securities stood at $1.54 billion on September 30, 2026.

Revenue jumps on Attruby and a milestone

BridgeBio Pharma (NASDAQ:BBIO) is a commercial-stage biopharmaceutical firm developing medicines for genetic diseases. Its lead product, acoramidis, is marketed in the United States as Attruby and in Europe, Japan and the United Kingdom as Beyonttra through partners. The company submitted its Quarterly Report for the period ended September 30, 2026 on October 29, 2026.

Total revenues rose $232.5 million from $120.7 million to $353.2 million, roughly 2.9 times the prior year level on a calculated basis. Net product revenue increased $145.3 million to $253.3 million, which management linked to continued commercial expansion fueled by patient demand.

License and services revenue reached $79.3 million, up from $8.3 million, mainly due to a $75.0 million sales milestone under the Bayer license agreement. Royalty revenue grew to $20.5 million from $4.3 million, reflecting Beyonttra sales in the EU and Japan.

Spending climbs, yet the operating loss shrinks

Loss from operations came to $11.6 million, compared with $145.2 million a year earlier. Cost of revenues was $20.5 million, up from $6.6 million.

Research and development expense rose $30.6 million to $143.5 million, driven by late-stage programs. Infigratinib was the largest program at $34.1 million, followed by acoramidis at $33.8 million, encaleret at $27.0 million and BBP-418 at $25.0 million.

Selling, general and administrative expense increased $63.2 million to $200.9 million, reflecting Attruby commercialization and pre-commercial work for late-stage candidates, including a $29.7 million rise in personnel costs.

Below the operating line

Net loss was $60.5 million versus $184.9 million. Noncash interest expense on deferred royalty obligations was $42.3 million, compared with $36.4 million, and the effective rate on that obligation rose to 22.2% from 21.3% after sales projections were revised upward.

Preferred stock dividends and accretion of $26.3 million were added to arrive at a net loss attributable to common stockholders of $83.0 million. That equals $0.42 per share, versus $0.95, on a weighted average of about 196.0 million shares.

Interest income rose to $13.1 million from $6.2 million, while the net loss from Equity method investments narrowed to $7.3 million from $15.8 million.

Nine months and a stronger balance sheet

Over nine months, total revenues were $791.4 million against $347.9 million, with net product revenue of $656.4 million. The net loss was $382.9 million, compared with $538.3 million, and net loss per share was $2.04 versus $2.79.

Cash, cash equivalents and marketable securities increased to $1.54 billion from $587.5 million at December 31, 2025. On July 1, 2026 the company sold Series A convertible preferred stock for $933.9 million, and in January 2026 it issued $632.5 million of 0.75% convertible senior notes due 2033.

Under a stock repurchase program approved in May 2026, it had bought 2,616,166 shares at an average of $66.88, or about $175.0 million, as of September 30, 2026. The $500.0 million at-the-market program remained unused.

Regulatory dates and what comes next

BBP-418 for LGMD2I/R9 carries a PDUFA target action date of November 27, 2026. Infigratinib for achondroplasia has a date of February 4, 2027, and encaleret for ADH1 has a date of May 8, 2027, all under Priority Review. Attruby also won approval in Australia in late October 2026.

Investors following the name will likely focus on the November 27 decision, whether product revenue holds without a milestone and how operating expenses develop as launches approach.